Biomolecules & therapeuticsJun 30, 2026

Cell Aging as a New Treatment Target for Idiopathic Pulmonary Fibrosis: Disease Causes and Treatment Approaches

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jul 1, 2026

Abstract

Cellular senescence may serve as a self-sustaining driver of progression in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis is characterized by irreversible lung tissue scarring and declining respiratory function.
Existing antifibrotic therapies can slow disease progression but do not reverse fibrosis.
Cellular senescence is increasingly recognized as a key process linked to aging and tissue repair failure in this disease.
Senescent cells release factors that activate fibroblasts and promote excessive tissue matrix deposition.
Transitional epithelial cell states that do not complete normal differentiation contribute to ongoing fibrotic remodeling.
Therapeutic strategies targeting senescent cells may enhance existing treatments and improve disease management.

Simplified

Idiopathic pulmonary fibrosis is a progressive and fatal lung disease characterized by irreversible tissue scarring, structural distortion, and declining respiratory function. Although currently approved antifibrotic therapies can slow disease progression, they do not stop or reverse fibrosis, highlighting the need to better understand upstream disease mechanisms. Increasing evidence identifies cellular senescence as a central biological process linking aging, epithelial cell vulnerability, mitochondrial dysfunction, and abnormal tissue repair in pulmonary fibrosis. Senescent epithelial and mesenchymal cells remain metabolically active and release a broad array of secreted factors that promote fibroblast activation, persistence of contractile cells, and excessive matrix deposition. Recent advances using single-cell and three-dimensional culture approaches further reveal the accumulation of transitional epithelial cell states that fail to complete normal differentiation and instead perpetuate fibrotic remodeling. These findings suggest that senescence represents not merely a consequence of tissue injury, but a self-sustaining driver of disease progression. This review integrates current mechanistic insights into how cellular senescence coordinates epithelial injury, immune dysregulation, and biomechanical feedback to drive lung fibrosis. We also discuss emerging therapeutic strategies that target senescent cells or their downstream signaling pathways, highlighting their potential to complement existing antifibrotic treatments and enable more effective disease modification.

Full Text

Full text is available at the source.

View Full Text ↗

Cell Aging as a New Treatment Target for Idiopathic Pulmonary Fibrosis: Disease Causes and Treatment Approaches

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief